JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan International Research Enhanced Equity ETF
JIRE
|
+$4.16B |
| 2 |
Microsoft
MSFT
|
+$2.29B |
| 3 |
Amazon
AMZN
|
+$2B |
| 4 |
UnitedHealth
UNH
|
+$1.76B |
| 5 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$1.42B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$4.61B |
| 2 |
Vanguard Short-Term Bond ETF
BSV
|
+$1.58B |
| 3 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$689M |
| 4 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$659M |
| 5 |
Invesco QQQ Trust
QQQ
|
+$647M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 26.28% |
| 2 | Technology | 15.04% |
| 3 | Healthcare | 12.52% |
| 4 | Financials | 10.55% |
| 5 | Consumer Discretionary | 7.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
TELL
2826
DELISTED
Tellurian Inc.
TELL
| $4.12M | ﹤0.01% |
1,381,959
+994,489
| +257% | +$4.6M |
2017 Q4
18 quarters
|
|
|
THS
2827
DELISTED
Treehouse Foods
THS
| $4.11M | ﹤0.01% |
98,175
+6,120
| +7% | +$225K |
2013 Q2
36 quarters
|
|
2828
Pacira BioSciences
PCRX
$1B
| $4.1M | ﹤0.01% |
70,406
+9,518
| +16% | +$623K |
2013 Q2
36 quarters
|
|
2829
Fidelity MSCI Financials Index ETF
FNCL
$2.23B
| $4.09M | ﹤0.01% |
91,666
+25,400
| +38% | +$1.24M |
2017 Q1
21 quarters
|
|
|
EVOP
2830
DELISTED
EVO Payments, Inc. Class A Common Stock
EVOP
| $4.09M | ﹤0.01% |
173,940
+148,634
| +587% | +$3.39M |
2018 Q2
16 quarters
|
|
2831
International Bancshares
IBOC
$4.34B
| $4.09M | ﹤0.01% |
102,040
-101,624
| -50% | -$4.14M |
2015 Q4
26 quarters
|
|
2832
IDT Corp
IDT
$1.96B
| $4.08M | ﹤0.01% |
162,322
-76,368
| -32% | -$2.11M |
2013 Q2
36 quarters
|
|
2833
PUT
Marriott International
MAR
$93.6B
| $4.08M | ﹤0.01% |
+30,000
| New | +$4.96M |
2022 Q2
0 quarters
|
|
|
POSH
2834
DELISTED
Poshmark, Inc. Class A Common Stock
POSH
| $4.08M | ﹤0.01% |
403,483
-48,359
| -11% | -$557K |
2021 Q1
5 quarters
|
|
2835
PUT
Hilton Worldwide
HLT
$71.9B
| $4.06M | ﹤0.01% |
36,400
-400
| -1% | -$55.3K |
2022 Q1
1 quarter
|
|
2836
Autohome
ATHM
$2.37B
| $4.05M | ﹤0.01% |
103,071
-83,843
| -45% | -$2.61M |
2017 Q2
20 quarters
|
|
2837
Capitol Federal Financial
CFFN
$1.06B
| $4.05M | ﹤0.01% |
440,967
+378,658
| +608% | +$3.74M |
2013 Q2
36 quarters
|
|
|
TWNI
2838
DELISTED
Tailwind International Acquisition Corp.
TWNI
| $4.05M | ﹤0.01% |
412,612
+347,307
| +532% | +$3.41M |
2021 Q4
2 quarters
|
|
2839
Teva Pharmaceutical Industries Limited
TEVA
$46.1B
| $4.05M | ﹤0.01% |
537,981
-7,310
| -1% | -$63.7K |
2013 Q2
36 quarters
|
|
2840
TripAdvisor
TRIP
$997M
| $4.04M | ﹤0.01% |
227,229
+44,558
| +24% | +$1.06M |
2013 Q2
36 quarters
|
|
2841
Fidelity MSCI Health Care Index ETF
FHLC
$3.39B
| $4.04M | ﹤0.01% |
66,618
+20,183
| +43% | +$1.25M |
2017 Q3
19 quarters
|
|
|
APTV.PRA
2842
DELISTED
Aptiv PLC 5.50% Series A Mandatory Convertible Preferred Shares
APTV.PRA
| $4.04M | ﹤0.01% |
38,306
-23,496
| -38% | -$2.79M |
2021 Q4
2 quarters
|
|
2843
PUT
Intuitive Surgical
ISRG
$138B
| $4.03M | ﹤0.01% |
20,100
+4,000
| +25% | +$938K |
2020 Q3
7 quarters
|
|
2844
CALL
Williams Companies
WMB
$86.3B
| $4.03M | ﹤0.01% |
129,000
+800
| +0.6% | +$27.6K |
2021 Q3
3 quarters
|
|
2845
Orthofix Medical
OFIX
$370M
| $4.03M | ﹤0.01% |
170,951
-1,601
| -0.9% | -$45.9K |
2015 Q2
28 quarters
|
|
2846
Calix
CALX
$2.19B
| $4.01M | ﹤0.01% |
117,411
-38,755
| -25% | -$1.44M |
2017 Q4
18 quarters
|
|
2847
iShares Core Universal USD Bond ETF
IUSB
$47.2B
| $4M | ﹤0.01% |
85,517
+11,802
| +16% | +$561K |
2020 Q2
8 quarters
|
|
2848
Corporacion America
CAAP
$3.97B
| $4M | ﹤0.01% |
716,443
+333,744
| +87% | +$2.06M |
2022 Q1
1 quarter
|
|
|
SJI
2849
DELISTED
South Jersey Industries, Inc.
SJI
| $3.99M | ﹤0.01% |
116,885
-310,568
| -73% | -$10.6M |
2016 Q4
22 quarters
|
|
2850
Armstrong World Industries
AWI
$6.89B
| $3.98M | ﹤0.01% |
53,139
+15,548
| +41% | +$1.31M |
2015 Q1
29 quarters
|
|
Similar funds
JP Morgan Chase's Q2 2022 Portfolio in Review
As of Q2 2022, JP Morgan Chase held 7,270 positions worth $718B, down 14% from $830B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
JP Morgan Chase's Q2 2022 filing shows 568 new, 2,561 increased, 2,728 reduced and 609 closed positions. Its largest new stake was JPMorgan International Research Enhanced Equity ETF: 85,906,762 shares worth $4.15B. The largest sale was JPMorgan BetaBuilders Europe ETF, an estimated $4.61B.
By sector, the portfolio is most concentrated in Miscellaneous at 26% of assets, down from 27% a quarter earlier, followed by Technology and Healthcare.
- JP Morgan Chase's largest Q2 2022 buy was JPMorgan International Research Enhanced Equity ETF: 85,906,762 shares worth $4.15B.
- JP Morgan Chase added most to Microsoft in Q2 2022, an estimated $2.29B increase.
- JP Morgan Chase's biggest Q2 2022 reduction was JPMorgan BetaBuilders Europe ETF, cutting an estimated $4.61B.
- JP Morgan Chase fully exited Cerner Corp in Q2 2022, selling an estimated $608M.
- JP Morgan Chase's ten largest holdings make up 18% of its $718B portfolio in Q2 2022.
- JP Morgan Chase opened 568 new positions and closed 609 in Q2 2022.
- JP Morgan Chase's portfolio value fell 14% quarter-over-quarter to $718B.
Based on JP Morgan Chase's 13F filing for Q2 2022, filed 11 Aug 2022.